Tokyo, Japan

Takeji Nishikawa

This inventor holds 3 USPTO granted patents. Top assignee: Keio University. Active years: 2006-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takeji Nishikawa. Retrieved from https://idiyas.com/inventor/takeji-nishikawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2006-2010

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Takeji Nishikawa: Innovator in Autoimmune Disease Research

Introduction

Takeji Nishikawa is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of autoimmune disease research, particularly in understanding and modeling conditions such as pemphigus vulgaris. With a total of 3 patents to his name, Nishikawa's work has the potential to impact therapeutic approaches for autoimmune diseases.

Latest Patents

Nishikawa's latest patents include innovative methods for creating animal models of autoimmune diseases. One of his notable inventions is an autoimmune disease model animal for pemphigus vulgaris (PV). This model is induced by an antibody against desmoglein 3 (Dsg3), which is crucial for understanding the disease's mechanisms. The persistent production of anti-Dsg3 IgG can be achieved by transferring spleen cells from a Dsg3 knockout mouse into an RAG2 knockout immunodeficient mouse expressing Dsg3 protein. This process leads to the development of symptoms characteristic of pemphigus vulgaris, such as blister formation in the oral mucosa.

Another significant patent involves a monoclonal antibody that can induce pemphigus lesions. This invention includes a peptide specifically recognized by the monoclonal antibody, which holds promise as a therapeutic drug for pemphigus autoimmune disease. By conducting cell fusion with splenocytes from a pemphigus vulgaris mouse model and mouse myeloma cells, Nishikawa successfully constructed hybridomas and screened for monoclonal antibodies against Dsg3. The identification of the specific epitope part and the determination of the base and amino acid sequences in the variable region of the antibody further enhance the potential for therapeutic applications.

Career Highlights

Nishikawa is affiliated with Keio University, where he continues to advance research in autoimmune diseases. His work has garnered attention for its innovative approaches to understanding complex immunological conditions.

Collaborations

Nishikawa has collaborated with notable colleagues such as Masayuki Amagai and Shigeo Koyasu. Their combined expertise has contributed to the development of groundbreaking research in the field of autoimmune diseases.

Conclusion

Takeji Nishikawa's contributions to autoimmune disease research through his patents and collaborations highlight his role as an influential inventor. His work not only enhances the understanding of pemph

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…